Get the Stockscreener App
2.61
4.40%
-0.12
After Hours:
2.63
0.02
+0.77%
Overview
News
Price History
Option Chain
Financials
Why SAVA Down?
Discussions
Forecast
Stock Split
Dividend History
Cassava Sciences Inc stock is traded at $2.61, with a volume of 740.43K.
It is down -4.40% in the last 24 hours and up +9.66% over the past month.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
See More
Previous Close:
$2.73
Open:
$2.73
24h Volume:
740.43K
Relative Volume:
0.31
Market Cap:
$126.08M
Revenue:
-
Net Income/Loss:
$-97.22M
P/E Ratio:
-1.8913
EPS:
-1.38
Net Cash Flow:
$-82.44M
1W Performance:
-7.45%
1M Performance:
+9.66%
6M Performance:
-90.72%
1Y Performance:
-87.36%
1-Day Range:
$2.60
$2.80
1-Week Range:
$2.49
$2.89
52-Week Range:
$2.23
$42.20
Cassava Sciences Inc Stock (SAVA) Company Profile
Name
Cassava Sciences Inc
Sector
Industry
Phone
512-501-2444
Address
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
Compare SAVA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SAVA
Cassava Sciences Inc
|
2.61 | 126.08M | 0 | -97.22M | -82.44M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-08-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-16-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-15-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-27-21 | Initiated | B. Riley Securities | Buy |
| Feb-16-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-18-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-15-20 | Downgrade | Maxim Group | Buy → Hold |
| Jan-10-20 | Reiterated | Maxim Group | Buy |
View All
Cassava Sciences Inc Stock (SAVA) Latest News
SAVA Deadline: SAVA Investors Have Opportunity to Lead Cassava S - GuruFocus.com
Cassava Sciences Amends Bonus Plan After Court Settlement - TipRanks
Cassava Sciences revises executive bonus plan - Investing.com
SAVA SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Cassava Sciences, Inc. Investors to Lead the Class Action Lawsuit! - ACCESS Newswire
Cassava Sciences (SAVA) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Cassava Sciences Reports 2024 Financial Results and Strategic Updates - TipRanks
H.C. Wainwright focused on what results from Cassava’s ReFocus-ALZ might reveal - Yahoo Finance
H.C. Wainwright maintains Neutral on Cassava Sciences stock By Investing.com - Investing.com Canada
SAVA Deadline Today: SAVA Investors Have Opportunity to Lead Cas - GuruFocus.com
Cassava: Low-Cost Pivot Into TSC Epilepsy Is Unlikely To Create Long-Term Value (SAVA) - Seeking Alpha
CASSAVA SCIENCES INC SEC 10-K Report - TradingView
LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer’s Treatments| DelveInsight - GlobeNewswire Inc.
Cassava Sciences Reports 2024 Financial Results and Provides Business Update - GlobeNewswire
Cassava Sciences reports Q4 EPS (57c) vs (50c) last year - TipRanks
Failed Alzheimer's Trial Forces Cassava Sciences to Pivot: Can Their $128M Cash Cushion Fund a Comeback? - StockTitan
ATTENTION Cassava Sciences, Inc. Investors: You May Have Been Affected by FraudContact Levi & Korsinsky to Discuss Your Rights - ACCESS Newswire
Cassava Sciences Licenses Simufilam Method of Treatment Patent - GlobeNewswire
Cassava Sciences Licenses Simufilam Patent From Yale University for Potential Treatment of Seizures; Shares Rise - Marketscreener.com
Cassava Sciences stock jumps on new patent license - Investing.com India
Cassava Sciences stock jumps on new patent license By Investing.com - Investing.com UK
Cassava Sciences Secures Exclusive License with Yale University - TipRanks
Can Simufilam Treat Rare Seizure Disorders? Yale Patent Boosts Cassava Sciences' Potential - StockTitan
Cassava Gears Up to Report Q4 Earnings: What's in the Cards? - MSN
UPCOMING SAVA DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Cassava Sciences, Inc. Investors to Lead the Class Action Lawsuit! - ACCESS Newswire
Class Action Lawsuit Filed Against Cassava Sciences (SAVA) Over Misleading Claims - PUNE.NEWS
Class Action Filed Against Cassava Sciences, Inc. (SAVA) Seeking Recovery for InvestorsContact Levi & Korsinsky - Stockhouse Publishing
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pen - GuruFocus.com
2025-02-10 | SAVA LAWSUIT ALERT: Levi & Korsinsky Notifies Cassava Sciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline | NDAQ:SAVA | Press Release - Stockhouse Publishing
SAVA Deadline Today: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit - PR Newswire
Cassava Sciences, Inc. Sued for Securities Law Violations – - GlobeNewswire
2025-02-10 | Cassava Sciences, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before February 10, 2025 to Discuss Your RightsSAVA | NDAQ:SAVA | Press Release - Stockhouse Publishing
2025-02-10 | Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc.(SAVA) Shareholders | NDAQ:SAVA | Press Release - Stockhouse Publishing
SAVA Lawsuit Alert! Class Action Against Cassava Sciences Inc. - TipRanks
2025-02-10 | FINAL REMINDER SAVA DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Cassava Sciences, Inc. Investors to Participate in the Class Action Lawsuit | NDAQ:SAVA | Press Release - Stockhouse Publishing
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 10, 2025 to Discuss Your RightsSAVA - Morningstar
SAVA DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, - GlobeNewswire
SAVA DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors - The Bakersfield Californian
Lead Plaintiff Deadline on February 10, 2025 for SAVA InvestorsKessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the Firm - Marketscreener.com
2025-02-09 | Cassava Sciences, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before February 10, 2025 to Discuss Your RightsSAVA | NDAQ:SAVA | Press Release - Stockhouse Publishing
2025-02-09 | FINAL SAVA DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Cassava Sciences, Inc. Investors to Join the Class Action Lawsuit | NDAQ:SAVA | Press Release - Stockhouse Publishing
SAVA Deadline in 1 Day: Kessler Topaz Meltzer & Check, LLP Reminds Cassava Sciences, Inc. (SAVA) Investors of Filing Deadline in Class Action Lawsuit | StreetInsider.com - Financial Content
2025-02-08 | Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your RightsSAVA | NDAQ:SAVA | Press Release - Stockhouse Publishing
SAVA Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP - GlobeNewswire
CASSAVA SCIENCES 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Cassava Sciences, Inc.SAVA - Business Wire
SAVA Deadline: Rosen Law Firm Urges Cassava Sciences, Inc. (NASDAQ: SAVA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - Business Wire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava - Marketscreener.com
2025-02-07 | SAVA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! | NDAQ:SAVA | Press Release - Stockhouse Publishing
Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - PR Newswire
CASSAVA SCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS - GlobeNewswire
Cassava Sciences, Inc. Sued for Securities Law ViolationsInve - GuruFocus.com
Perhaps timely catching Cassava Sciences Inc (SAVA) would be a good idea - SETE News
Cassava Sciences Inc Stock (SAVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):